ABT-199
|
|
|
- CAS-Nr.
- 1257044-40-8
- Englisch Name:
- ABT-199
- Synonyma:
- Venetoclax;Venclexta;ATB199;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami;GDC-0199;Venetoclax (ABT-199, GDC-0199);2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199);S8048
- CBNumber:
- CB62645962
- Summenformel:
- C45H50ClN7O7S
- Molgewicht:
- 868.44
- MOL-Datei:
- 1257044-40-8.mol
|
ABT-199 Eigenschaften
- Schmelzpunkt:
- >150°C (dec.)
- Dichte
- 1.340±0.06 g/cm3(Predicted)
- storage temp.
- -20°C Freezer
- L?slichkeit
- DMSO (Slightly)
- Aggregatzustand
- Yellow solid.
- pka
- 4.09±0.10(Predicted)
- Farbe
- Light Yellow to Yellow
- InChIKey
- LQBVNQSMGBZMKD-UHFFFAOYSA-N
- SMILES
- C(NS(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)(=O)=O)(=O)C1=CC=C(N2CCN(CC3CCC(C)(C)CC=3C3=CC=C(Cl)C=C3)CC2)C=C1OC1=CN=C2NC=CC2=C1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H361 |
Kann vermutlich die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. |
Reproduktionstoxizit?t |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
| H372 |
Sch?digt bei Hautkontakt und Verschlucken die Organe bei l?ngerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
P260, P264, P270, P314, P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P281 |
Vorgeschriebene pers?nliche Schutzausrüstung verwenden. |
| P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P314 |
Bei Unwohlsein ?rztlichen Rat einholen / ?rztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
ABT-199 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Venetoclax, codeveloped by
AbbVie (previously Abbott Laboratories) and Genentech/
Roche, was approved in the US for treatment of patients with
chronic lymphocytic leukemia (CLL). To meet qualifications
for venetoclax treatment, patients must have received prior
therapy and possess the 17p deletion genetic mutation, as
determined by USFDA testing. Venetoclax functions as a
selective inhibitor of B cell lymphoma subtype 2 (BCL-2),
which is often overexpressed on malignant cells and thus leads
to impairment of the apoptotic pathway. Along these lines,
the orally dosed small molecule drug restores the ability of
malignant cells to undergo apoptosis as its mechanism of
action.90 Although other BCL-2 inhibitors are known, development
of similar agents such as navitoclox have been pursued
and halted due to undesired inhibition of BCL-XL, leading to
significant thrombocytopenia and demonstrating the need for
more selective inhibitors. Venetoclax is also currently being
considered for approval in Europe and Canada for similar
indications and is in various stages of development for the
treatment of non-Hodgkin lymphomas (NHL), acute myeloid
leukemia (AML), multiple myeloma (MM), and several other
disorders, either as a combination therapy or a stand-alone
treatment.
Definition
ChEBI: A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.
ABT-199 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
ABT-199 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 471)Lieferanten
- ABT-199
- ABT-199 (GDC-0199);GDC-0199
- ABT-199 100MG
- 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)met
- ABT-199, Venetoclax
- GDC 0199
- GDC0199
- Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-
- ABT 199
4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide
- 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide
- 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
- Venetoclax (ABT-199)
- 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]
- ABT199,GDC0199
- ABT-199, >=98%
- 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1
-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Venetoclax)(ABT199)
- Venclexta(abt199)
- ABT-199, Venetoclax, GDC-0199
- ABT-199 (GDC-0199)Venetoclax
- ABT199; GDC0199;ABT 199;GDC 0199;GDC-0199
- CS-679
- 105148
- ABT199;GDC0199;ABT 199;GDC 0199;GDC-0199;VENETOCLAX
- D00PBX
- rg7601
- S8048
- W-6008
- X3609
- Z-3166
- 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
- 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Venetoclax)
- 99%)
(Venetoclax)
- ABT 199 (>
- ABT-199 USP/EP/BP
- Venetoclax trifluoroacetate salt
- ABT 199 (>99%)
(Venetoclax)
- 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-e
n-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4
-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[
2,3-b]pyridin-5-yloxy}benzamide
- 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexy-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsuflonyl)benzamide
- Venetoclax 95%
- 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide
- 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199)
- Venetoclax
- 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami
- Venclexta
- ATB199
- Venetoclax (ABT-199, GDC-0199)
- 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy
- D torah
- GDC-0199
- BT-199
- bioavailable,orally,Venetoclax,inhibit,Inhibitor,Bcl-2 Family,GDC0199,GDC 0199,Autophagy
- Venetoclax ABT199 ABT-199
- 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
- Venetola
- Vinetola
- ABT-199 (Venetoclax), Bcl-2 inhibitor.
- Venetoclax, 10 mM in DMSO
- 1257044-40-8
